-
Xibiman Biotechnology and AstraZeneca have reached a joint development agreement to jointly develop and commercialize a new GPC3 armored CAR-T therapy in China
Our reporter Xu Yiming, intern journalist Jin Wanxia Recently, Sibyman Biotechnology Group (hereinafter referred to as Sibyman) announced the signing of a joint development agreement with AstraZeneca ...- suisuiblue
- 2023-12-10
- サポート
- に反対
- 返信
- コレクション